Home > Inhibitors & Agonists > Others

Others

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC0965 Bgt1-in-9 The first small-molecule substrate identified with high selectivity for BGT1 over the three other GAT subtypes; M1 muscarinic agonist
DCC0966 Bh3i-2 Cell-permeable apoptosis inducer, specifically preventing BH3 domain-mediated interactions between pro-apoptotic and anti-apoptotic members of the Bcl-2 family
DCC0967 Bhq-2-succinimide Ester Reactive dark quencher used in a variety of Fluorescence Resonance Energy Transfer (FRET) DNA detection probe.
DCC0968 Bhq-o-5ht Novel photoactivatable form of serotonin
DCC0969 Bi-0319 Novel PROTAC (proteolysis-targeting chimera) as a PTK2 protein degerader
DCC0970 Bi-1750 Featured BI-1750 is a highly selective and stable fluorogenic substrate designed for Cathepsin C (CatC), a lysosomal cysteine protease involved in various physiological and pathological processes. Its unique properties make it a powerful tool for studying CatC activity in both research and drug development contexts.
DCC0971 Bi-1942 Novel potent inhibitor of human chymase with >100 fold selectivity against Cathepsin G
DCC0972 Bi-2051 Novel highly selective, soluble and cellular permeable inhibitor of the P. falciparum protease dipeptidyl aminopeptidase 1 (DPAP1)
DCC0973 Bi-3257 Novel inhibitor of HIV replication, preventing the formation of the capsid core structure that encapsulates the viral genome and its associated enzymes, reversing transcriptase and integrase
DCC0974 Bi-4659 Novel potent and selective inhibitor of Alk5 (TGFßR1), blocking the phosphorylation of Smad2 and Smad3 in HaCaT cells
DCC0975 Bi-5521 Novel potent and selective ATP-competitive inhibitor of glycogen synthase kinase (GSK-3), targeting both isoforms GSK-3α and GSK-3β
DCC0976 Bi-7273 Novel highly potent dual inhibitor of BRD9/BRD7
DCC0977 Bi-730357 Novel RORγ antagonist for the treatment of autoimmune diseases
DCC0978 bi-83c11 Non-ATP competitive inhibitor of JNK, targeting the JNK-JIP interaction
DCC0979 Bi-9740 Novel potent, highly selective, and orally bioavailable CATHEPSIN C (CTSC, CatC) inhibitor
DCC0980 Bibs-222 Novel nonpeptide angiotensin II receptor antagonist
DCC0981 Bi-btk-1 Novel, highly selective and potent irreversible BTK inhibitor
DCC0982 Bibx-1382 Dihydrochloride Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase
DCC0983 Bicifadine Triple reuptake inhibitor (TRI)
DCC0984 Biclofibrate Antilipidemic agent
DCC0985 bicuculline Methobromide GABAA receptor antagonist
DCC0986 Biemamide A Novel inhibitor of the TGF-β pathway, blocking the epithelial to mesenchymal transition
DCC0987 Bifeprunox Mesylate Partial agonist at dopamine D2 and serotonin 1A receptors
DCC0988 Biib028 Novel selective heat shock protein 90 inhibitor, prodrug of CF2772
DCC0989 Biib-057 Selective Syk inhibitor
DCC0990 Biib068 Hemi-adipate Novel, Selective, Potent, Reversible Bruton's Tyrosine Kinase (BTK) Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
DCC0991 Biii-277cl Novel potent blocker of the NMDA receptor ion channel
DCC0992 Biii-890cl Novel potent blocker of Nav1.2 sodium channels, protecting of brain tissue from ischemia
DCC0993 Biliatresone Natural Biliary Toxin, causing extrahepatic biliary atresia
DCC0994 bim5078 Potent HNF4α antagonist

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X
>